Startup valuations since Q1 2021 in 4 major industries. Who is holding up best?
Yesterday we looked at how late-stage venture is declining much more quickly than early-stage. Today we split those earlier rounds by 4 industries: SaaS, Consumer, Fintech, and Healthtech.
Notes on this data before jumping in - all of it comes from Carta cap table companies (35,000+ of them now). The graphics only include U.S. startups and comes from a robust 7,000+ rounds.
We only plotted valuation changes, but know that round volume changes are also occurring (fewer rounds are happening in each successive quarter).
Percentage change refers to the difference in the median pre-money valuation by quarter compared with Q1 2021.
𝗦𝗲𝗲𝗱
Healthtech is the...healthiest here, at 57% above Q1 2021 levels.
SaaS and Consumer both above the starting point
Fintech falling fastest
𝗦𝗲𝗿𝗶𝗲𝘀 𝗔
Healthtech leads again!
Down between 15% and 17% in Consumer and Fintech
SaaS basically flat
𝗦𝗲𝗿𝗶𝗲𝘀 𝗕
SaaS is lowest here (down 35%)
Fintech basically flat (after some serious spike in prior quarters)
Dynamics are clearly different by industry - but it does seem that Fintech is getting roughed up more in the earliest stages and Healthtech valuations are relatively more bouyant.
Get Q1 2023 data in your inbox the moment it's ready by signing up to our Data Minute newsletter in the first comment below.
#cartadata #healthtech #saas #fintech #consumertech #startups #valuations
DISCLOSURE: This communication is on behalf of eShares, Inc. dba Carta, Inc. ("Carta"). This communication is for informational purposes only, and contains general information only. Carta is not, by means of this communication, rendering accounting, business, financial, investment, legal, tax, or other professional advice or services. This publication is not a substitute for such professional advice or services nor should it be used as a basis for any decision or action that may affect your business or interests. Before making any decision or taking any action that may affect your business or interests, you should consult a qualified professional advisor. This communication is not intended as a recommendation, offer or solicitation for the purchase or sale of any security. Carta does not assume any liability for reliance on the information provided herein. © 2026 Carta. All rights reserved. Reproduction prohibited.
